1. Home
  2. LIEN vs RIGL Comparison

LIEN vs RIGL Comparison

Compare LIEN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIEN
  • RIGL
  • Stock Information
  • Founded
  • LIEN 2021
  • RIGL 1996
  • Country
  • LIEN United States
  • RIGL United States
  • Employees
  • LIEN N/A
  • RIGL N/A
  • Industry
  • LIEN
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIEN
  • RIGL Health Care
  • Exchange
  • LIEN NYSE
  • RIGL Nasdaq
  • Market Cap
  • LIEN 234.6M
  • RIGL 335.5M
  • IPO Year
  • LIEN 2022
  • RIGL 2000
  • Fundamental
  • Price
  • LIEN $10.29
  • RIGL $18.62
  • Analyst Decision
  • LIEN Buy
  • RIGL Buy
  • Analyst Count
  • LIEN 2
  • RIGL 5
  • Target Price
  • LIEN N/A
  • RIGL $36.40
  • AVG Volume (30 Days)
  • LIEN 56.1K
  • RIGL 192.9K
  • Earning Date
  • LIEN 08-07-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • LIEN 13.25%
  • RIGL N/A
  • EPS Growth
  • LIEN 30.25
  • RIGL N/A
  • EPS
  • LIEN 1.15
  • RIGL 2.08
  • Revenue
  • LIEN $30,828,508.00
  • RIGL $203,077,000.00
  • Revenue This Year
  • LIEN $154.46
  • RIGL $14.41
  • Revenue Next Year
  • LIEN $10.64
  • RIGL $15.97
  • P/E Ratio
  • LIEN $8.90
  • RIGL $9.02
  • Revenue Growth
  • LIEN 151.96
  • RIGL 70.16
  • 52 Week Low
  • LIEN $9.70
  • RIGL $7.48
  • 52 Week High
  • LIEN $13.38
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • LIEN N/A
  • RIGL 39.75
  • Support Level
  • LIEN N/A
  • RIGL $18.14
  • Resistance Level
  • LIEN N/A
  • RIGL $19.21
  • Average True Range (ATR)
  • LIEN 0.00
  • RIGL 0.84
  • MACD
  • LIEN 0.00
  • RIGL -0.28
  • Stochastic Oscillator
  • LIEN 0.00
  • RIGL 10.89

About LIEN CHICAGO ATLANTIC BDC INC

Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: